Compare MX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MX | VANI |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.0M | 92.6M |
| IPO Year | N/A | 2014 |
| Metric | MX | VANI |
|---|---|---|
| Price | $2.61 | $1.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $5.75 | $4.00 |
| AVG Volume (30 Days) | ★ 323.7K | 202.0K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,755,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.62 | N/A |
| 52 Week Low | $2.18 | $0.91 |
| 52 Week High | $5.16 | $1.92 |
| Indicator | MX | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 36.52 |
| Support Level | $2.55 | $1.36 |
| Resistance Level | $2.81 | $1.46 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 13.95 | 5.88 |
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.